Of critical interest is the long survival observed in 7 of the 37 vaccinated patients (2 with mutated IDH-1 and 5 wild type), who remain alive to this day (mean OS of 48 months, or 34 months after vaccination began) without evidence of tumor recurrence. The gene discussed is IDH1; the disease is neoplasm.